(2S)-1-(Tert-Butoxycarbonyl)-5-Methylpyrrolidine-2-Carboxylic Acid

Incorporation of (2S)-1-(tert-butoxycarbonyl)-5-methylpyrrolidine-2-carboxylic acid into peptide backbones via standard Fmoc solid-phase peptide synthesis constitutes the most prevalent downstream application, driven by the demand for conformationally restricted proline analogs in lead optimization programs. Pre-weighed resin-bound amino acids—typically a Rink amide AM resin with a substitution of 0.4–0.6 mmol/g or a preloaded Wang resin—are swollen in DMF (dimethylformamide) for 30 min at ambient temperature. After Fmoc deprotection with 20% (v/v) piperidine in DMF under nitrogen overlay, the deprotected resin is washed sequentially with DMF and DCM. The Boc-5-methylproline derivative is dissolved in DMF to a concentration of 0.3–0.5 M and activated using 2.5–4.0 equiv. of HATU (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate) together with 5.0–8.0 equiv. of DIPEA (N,N-diisopropylethylamine), relative to the resin loading. Coupling is allowed to proceed for 45–90 min, with reaction progress monitored by the Kaiser ninhydrin test (free amine detection). Incomplete couplings—frequently observed at sterically hindered sites—are mitigated by double coupling or switching to HATU/HOAt/Oxyma Pure activation cocktails in DMF/DCM mixtures. Following chain assembly, global deprotection and cleavage are carried out with a reagent mixture of TFA/TIS/H₂O (95:2.5:2.5 v/v) for 2–3 h at room temperature, which simultaneously removes the Boc protecting group and cleaves the peptide from the resin. The crude peptide is precipitated in cold diethyl ether, lyophilized, and purified by preparative RP-HPLC (C18 column, 250×21.2 mm, 5 μm particle size) using a linear gradient of acetonitrile in water with 0.1% TFA. Regulatory compliance for such intermediates destined for GMP-grade peptide APIs follows ICH Q7 Section 19 (APIs for clinical trials), ICH Q3C (residual solvents: DMF limit 880 ppm, acetonitrile limit 410 ppm), and USP <231> heavy metals (≤20 ppm). The intermediate itself must meet acceptance criteria of purity ≥98.0% by HPLC at 220 nm, enantiomeric excess ≥99.0% by chiral HPLC (Chiralpak IA column, hexane/isopropanol/TFA mobile phase), and water content ≤0.5% by Karl Fischer titration. End-product classes incorporating this scaffold include constrained peptide agonists targeting GPCRs (e.g., apelin receptor), stabilized analogs of linear antimicrobial peptides (e.g., magainin II derivatives with improved serum half-life), and peptidomimetic inhibitors of protein–protein interactions where the 5-methyl substitution on the pyrrolidine ring reduces backbone flexibility and favors the cis-amide conformation required for bioactivity.

What Stoichiometric Adjustments Are Required When Introducing 5-Methylproline in Microwave-Assisted SPPS?

Microwave-enhanced solid-phase peptide synthesis operating at 2450 MHz in instruments such as the CEM Liberty Blue or Biotage Initiator+ Alstra imposes thermal and kinetic constraints that demand reformulation of standard coupling protocols for Boc-5-methylproline. Unlike common amino acids, the steric bulk of the C5 methyl group and the slow ring-puckering dynamics of the pyrrolidine ring significantly retard acylation rates; consequently, the combination of elevated temperature and prolonged irradiation without precise stoichiometric control induces Cα-epimerization via oxazolone formation. The recommended molar excess relative to resin loading is reduced to 1.8–2.5 equiv. when using pre-activation with ethyl cyanoglyoxylate-2-oxime (Oxyma Pure) and N,N′-diisopropylcarbodiimide (DIC) in DMF at 50°C, with a coupling time not exceeding 4 min for a 0.1 mmol scale synthesis. The pre-activation vessel is held at 25°C for 90 s prior to transfer, and the reaction cell temperature is ramped from 25°C to 50°C over 60 s at 35 W maximum power. Real-time deprotection monitoring via UV absorbance at 304 nm (Fmoc-piperidine adduct) ensures that incomplete deprotection does not propagate sequence deletions. A critical processing window exists: if the reactor temperature exceeds 55°C during the coupling step, Boc group lability increases, leading to premature N-terminal exposure and double incorporation, which elevates the des-methyl byproduct level above 0.3% area-normalized HPLC. The addition of 0.1 M LiCl in DMF as a chaotropic agent disrupts peptide aggregation on the resin and improves coupling efficiency by 12–18%, as quantified by Fmoc-Dab(ivDde) internal standard analysis. Regulatory oversight for microwave-produced peptide intermediates adheres to the same ICH Q7 framework, but with additional process analytical technology (PAT) documentation demonstrating real-time temperature and pressure traces, and batch records that reference 21 CFR Part 11 compliant electronic signatures on the automated synthesizer. End-use products span photoaffinity-labeled analogs of constrained helical peptides used in cellular target engagement studies, as well as methylproline-containing stapled peptides synthesized via ring-closing metathesis on solid support, where the Boc intermediate must assay at ≤0.1 EU/mg bacterial endotoxins per USP <85> when intended for in vivo pharmacological evaluation.

The use of (2S)-1-(tert-butoxycarbonyl)-5-methylpyrrolidine-2-carboxylic acid as a proline surrogate in solution-phase fragment condensation enables late-stage introduction of a methyl-substituted pyrrolidine motif into macrocyclic scaffolds without exposing the full synthesis to solid-phase scale limitations. A representative sequence involves the preparation of a tetrapeptide carboxylic acid intermediate via a C-to-N direction solution-phase coupling strategy, where the Boc-5-methylproline is coupled as the N-terminal residue using T3P (propylphosphonic anhydride, 50% in ethyl acetate, 1.5 equiv.) and N-methylmorpholine (3.0 equiv.) in ethyl acetate at 0–5°C, with the temperature kept at ≤5°C for 30 min to suppress epimerization at the chiral center adjacent to the carboxylic acid. After aqueous workup with 1 M HCl and saturated NaHCO₃, the Boc group is removed using 4 M HCl in 1,4-dioxane at 10°C for 1 h, liberating the amine hydrochloride in crystalline form upon precipitation with diethyl ether. This fragment is subsequently condensed with a pre-formed macrocyclic acid bearing a C14–C19 alkyl chain and a triazole heterocycle—common in hepatitis C virus NS3/4A protease inhibitor pharmacophores—using HATU (1.05 equiv.) and collidine (3.0 equiv.) in DMF at −10°C. The coupling yield ranges 72–85% after flash chromatography (silica gel, hexane/ethyl acetate gradient). Compliance in this synthetic route is governed by ICH Q11 (development and manufacture of drug substances), requiring full characterization of the starting material by 1H, 13C NMR, HRMS, and IR, as well as demonstration of process-related impurity control for the des-methyl analog and the epimeric (2R)-diastereomer to levels below 0.15% each by a validated UPLC method equipped with a sub-2-µm C18 column. Residual elementals must meet ICH Q3D limits for Class 1 and 2A elements, with particular attention to palladium (≤10 ppm) if hydrogenation steps are used earlier in the sequence. The final constructs are macrocyclic peptidomimetics with molecular weights ranging 550–800 Da, investigated as antiviral agents and cyclophilin inhibitors, where the 5-methylproline residue reinforces a type VI β-turn conformation and raises metabolic stability by shielding the adjacent amide bond from peptidase cleavage in liver microsome assays (t_1/2 extension by a factor of 3–8 compared to des-methyl analogs).

Polyproline Helix II Induction and cis/trans Isomerization Studies Using Homooligomer Libraries

Conformational analysis of (2S)-1-(tert-butoxycarbonyl)-5-methylpyrrolidine-2-carboxylic acid homooligomers (n = 3–6) synthesized by iterative coupling in DMF with DIC/HOBt provides quantitative data on the influence of the C5 methyl substituent on prolyl amide bond geometry. Oligomers are assembled on a 2-chlorotrityl chloride resin preloaded with the first Boc-protected residue at 0.3 mmol/g, and each elongation cycle uses 3.0 equiv. of the amino acid and 3.0 equiv. of HOBt/DIC in DMF for 2 h. After NH₃/MeOH cleavage, the protected oligomers are purified by silica gel column chromatography and characterized by circular dichroism spectroscopy in water and trifluoroethanol. The CD spectra at –50°C to 25°C reveal a characteristic polyproline II helix signature with a negative band at 205 nm and a positive band at 225 nm, whose intensity per residue increases monotonically from dimer to hexamer. Quantitative 1H-13C heteronuclear single quantum coherence (HSQC) NMR at 600 MHz in D₂O (pD 4.0) resolves the cis and trans conformer populations at the Xaa-5-methylPro amide bond; the trans content drops from 78% for the dimer to 68% for the hexamer, indicating that chain elongation favors the all-cis polyproline I helix under these conditions. Such model systems serve as calibration standards for spectroscopic analysis of 5-methylproline-containing peptide drugs during forced degradation studies, and the fully characterized Boc-monomer must conform to analytical specifications identical to those in the quality attributes table above, with additional specific optical rotation ([α]_D²⁰ = –52°±2° (c = 1.0, MeOH)) that acts as an identity test per USP <781>. The terminal products are not therapeutic agents but rather reference standards and conformational probes distributed to structural biology laboratories under ISO 17034 accredited reference material frameworks, accompanied by certificates of analysis reporting extended uncertainty budgets for purity and enantiomeric excess.

When 2,5-Disubstituted Pyrrolidine Replacement of Native Proline Improves Proteolytic Stability in Bioactive Peptides

Sequential replacement of naturally occurring proline residues with (2S)-1-(tert-butoxycarbonyl)-5-methylpyrrolidine-2-carboxylic acid in linear bioactive peptides—such as bradykinin, angiotensin II, or apidaecin-type antimicrobial sequences—is executed through a standard Fmoc-SPPS protocol on a Tentagel S RAM resin (0.25 mmol/g), but with adjusted coupling cycles for each 5-methylproline position. Each insertion requires 3.5 equiv. of the Boc-protected monomer, 3.5 equiv. of PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate), and 7.0 equiv. of DIPEA in NMP (N-methyl-2-pyrrolidone) at 40°C for 60 min, double-coupled if the preceding residue is a β-branched amino acid. NMP is preferred over DMF to reduce racemization during prolonged heating, as confirmed by Marfey’s analysis of hydrolyzed peptide aliquots. Where consecutive 5-methylproline residues are introduced, a capping step with acetic anhydride/pyridine (1:1, v/v) for 10 min is implemented after each coupling to prevent deletion sequences. Final peptide products are cleaved with reagent K (TFA/phenol/water/thioanisole/EDT, 82.5:5:5:5:2.5 v/v) and purified to ≥95% purity by RP-HPLC. Regulatory compliance for modified peptides evaluated as preclinical candidates invokes ICH S6 (preclinical safety evaluation of biotechnology-derived pharmaceuticals) when the sequences exceed 40 amino acids, and general drug substance guidelines ICH Q6A for smaller synthetic peptides. Stability-indicating assays must demonstrate ≤0.5% epimer at each 5-methylproline insertion site, and the entire sequence is subjected to forced degradation at 40°C/75% RH for 4 weeks with weekly chiral HPLC monitoring. End-product applications encompass methicillin-resistant Staphylococcus aureus (MRSA) membrane-disrupting peptoids containing multiple 5-methylproline units that confer resistance to serum protease degradation, as well as long-acting bradykinin B2 receptor antagonists for hereditary angioedema, where the methyl group sterically hinders attack by angiotensin-converting enzyme and extends circulatory half-life to 3–6 h in rat pharmacokinetic models.